OrthoPediatrics reported a 19% increase in Q3 2026 revenue to $72.7 million, driven by growth in trauma, deformity, and scoliosis products. The company improved profitability with record adjusted EBITDA of $6.9 million and positive free cash flow of $1.6 million. It raised its full-year 2026 revenue guidance to $270-$273 million, expecting 14-16% growth over 2025. OrthoPediatrics plans to continue expanding its pediatric orthopedic product portfolio and aims for breakeven free cash flow in 2026 and beyond.
OrthoPediatrics Corp.'s third quarter 2026 results and guidance update provide context for readers. For those tracking the health sector, 88 of 150 US health stocks on Pluang rose while 62 fell. Notable movers include NUWE at USD 5.06 with a 65.36% increase and 100% sell order activity, CTXR at USD 0.51 up 13.82%, and DNA at USD 11.21 up 11.93%. Data is as of Oct 28, 2026 03:11 WIB.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
